TP53 and neoplasm: GO analysis of 350 genes that were differentially methylated between HR+ and HR- breast tumors identified 71 GO terms that remained highly significant after adjusting for multiple comparisons (FDR adjusted P <0.05); similarly, GO analysis for 264 genes differentially methylated between luminal A and basal tumor subtypes identified 36 terms, and analysis of 296 genes differentially methylated between p53 mutant and wild-type tumors identified 44 GO terms.